Post-transplant lymphoproliferative disease
disease diseaseOn this page
Also known as post-transplant lymphoproliferative disorderPTLD
Summary
Post-transplant lymphoproliferative disease (MONDO:0019088) is a disease and 64 clinical trials. Top therapeutic interventions include fludarabine phosphate, foscarnet, and cyclophosphamide anhydrous. A subtype of disease related to transplantation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 16
- Clinical trials: 64
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 26.2 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
16 HPO clinical features (Orphanet curated; top 16 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001608 | Abnormality of the voice | Frequent (30-79%) |
| HP:0001824 | Weight loss | Frequent (30-79%) |
| HP:0001945 | Fever | Frequent (30-79%) |
| HP:0002716 | Lymphadenopathy | Frequent (30-79%) |
| HP:0004396 | Poor appetite | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0025267 | Snoring | Frequent (30-79%) |
| HP:0030166 | Night sweats | Frequent (30-79%) |
| HP:0033050 | Pharyngalgia | Frequent (30-79%) |
| HP:0033834 | Malaise | Frequent (30-79%) |
| HP:0002014 | Diarrhea | Occasional (5-29%) |
| HP:0002027 | Abdominal pain | Occasional (5-29%) |
| HP:0002239 | Gastrointestinal hemorrhage | Occasional (5-29%) |
| HP:0003073 | Hypoalbuminemia | Occasional (5-29%) |
| HP:0012115 | Hepatitis | Occasional (5-29%) |
| HP:0033608 | Pulmonary nodule | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | post-transplant lymphoproliferative disease |
| Mondo ID | MONDO:0019088 |
| Orphanet | 70568 |
| ICD-10-CM | D47.Z1 |
| NCIT | C4727 |
| SNOMED CT | 254290004 |
| UMLS | C0432487 |
| MedGen | 98160 |
| GARD | 0009553 |
| MedDRA | 10051358 |
| NORD | 1950 |
| Is cancer (heuristic) | no |
Also known as: post-transplant lymphoproliferative disorder · PTLD
Data availability: 1 cell line.
Disease family
This is a subtype of disease related to transplantation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › disease related to transplantation › post-transplant lymphoproliferative disease
Related subtypes (4): posttransplant acute limbic encephalitis, disease related to solid organ transplantation, disease related to hematopoietic stem cell transplant, transplant rejection
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 64.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 18 |
| PHASE1 | 17 |
| PHASE1/PHASE2 | 13 |
| Not specified | 12 |
| EARLY_PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01088724 | PHASE4 | COMPLETED | Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) |
| NCT03386539 | PHASE3 | ACTIVE_NOT_RECRUITING | Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score |
| NCT05688241 | PHASE1/PHASE2 | NOT_YET_RECRUITING | EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases |
| NCT06040320 | PHASE1/PHASE2 | RECRUITING | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) |
| NCT07368634 | PHASE1/PHASE2 | RECRUITING | Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation |
| NCT07438067 | PHASE1/PHASE2 | RECRUITING | EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation |
| NCT07573436 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) |
| NCT00006251 | PHASE1/PHASE2 | COMPLETED | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
| NCT00049504 | PHASE2 | COMPLETED | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
| NCT00064246 | PHASE1/PHASE2 | COMPLETED | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder |
| NCT00078858 | PHASE1/PHASE2 | COMPLETED | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
| NCT00089011 | PHASE2 | COMPLETED | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
| NCT00590447 | PHASE2 | COMPLETED | Risk Stratified Sequential Treatment for CD20-positive PTLD |
| NCT00867529 | PHASE2 | COMPLETED | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
| NCT00918333 | PHASE1/PHASE2 | COMPLETED | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
| NCT01058239 | PHASE2 | COMPLETED | Bortezomib Plus Rituximab for EBV+ PTLD |
| NCT01075321 | PHASE1/PHASE2 | COMPLETED | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
| NCT01177371 | PHASE2 | COMPLETED | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
| NCT01261247 | PHASE2 | COMPLETED | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
| NCT01427881 | PHASE2 | COMPLETED | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
| NCT01434472 | PHASE2 | TERMINATED | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma |
| NCT01529827 | PHASE2 | COMPLETED | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT01652014 | PHASE2 | WITHDRAWN | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies |
| NCT01789255 | PHASE2 | COMPLETED | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
| NCT01805037 | PHASE1/PHASE2 | TERMINATED | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
| NCT01839916 | PHASE2 | COMPLETED | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT01964755 | PHASE2 | TERMINATED | Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma |
| NCT02580539 | PHASE1/PHASE2 | COMPLETED | A Study of the Safety and Efficacy of EBV Specific T-cell Lines |
| NCT02763254 | PHASE2 | TERMINATED | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas |
| NCT03086395 | PHASE2 | WITHDRAWN | Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) |
| NCT04138875 | PHASE2 | WITHDRAWN | A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) |
| NCT04337827 | PHASE2 | TERMINATED | Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder |
| NCT04507477 | PHASE1/PHASE2 | UNKNOWN | Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial |
| NCT01815749 | PHASE1 | ACTIVE_NOT_RECRUITING | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
| NCT02153580 | PHASE1 | ACTIVE_NOT_RECRUITING | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia |
| NCT06666153 | PHASE1 | NOT_YET_RECRUITING | Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases |
| NCT07614282 | PHASE1 | NOT_YET_RECRUITING | Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia |
| NCT00036855 | PHASE1 | TERMINATED | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma |
| NCT00348985 | PHASE1 | COMPLETED | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
| NCT00354185 | PHASE1 | TERMINATED | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 12 |
| FOSCARNET | 4 | 4 |
| CYCLOPHOSPHAMIDE ANHYDROUS | 4 | 3 |
| DOXORUBICIN | 4 | 3 |
| YTTRIUM Y 90 IBRITUMOMAB TIUXETAN | 4 | 3 |
| BELINOSTAT | 4 | 2 |
| PANOBINOSTAT | 4 | 2 |
| ACALABRUTINIB | 4 | 1 |
| AZACITIDINE | 4 | 1 |
| BENDAMUSTINE | 4 | 1 |
| BRENTUXIMAB VEDOTIN | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| HYDROXYUREA | 4 | 1 |
| LONCASTUXIMAB TESIRINE | 4 | 1 |
| OBINUTUZUMAB | 4 | 1 |
| POLATUZUMAB VEDOTIN | 4 | 1 |
| RITUXIMAB | 4 | 1 |
| VALGANCICLOVIR | 4 | 1 |
| INDIUM IN 111 IBRITUMOMAB TIUXETAN | 3 | 2 |
| FLUDARABINE | 3 | 1 |
| QS-21 | 3 | 1 |
| TANESPIMYCIN | 3 | 1 |
| AR-42 | 2 | 1 |
| BALTALEUCEL-T | 2 | 1 |
| CHLORHEXIDINE PHOSPHANILATE | 1 | 1 |
| CHEMBL344227 | 0 | 2 |
| CHEMBL290077 | 0 | 1 |
| CHEMBL4747506 | 0 | 1 |
| CHEMBL5187554 | 0 | 1 |
| CHEMBL5276925 | 0 | 1 |
Related Atlas pages
- Drugs: Fludarabine Phosphate, Foscarnet, Cyclophosphamide, Doxorubicin, YTTRIUM Y 90 IBRITUMOMAB TIUXETAN, Belinostat, Panobinostat, Acalabrutinib, Azacitidine, Bendamustine, Brentuximab Vedotin, Ganciclovir, Hydroxyurea, Loncastuximab Tesirine, Obinutuzumab, Polatuzumab Vedotin, Rituximab, Valganciclovir, INDIUM IN 111 IBRITUMOMAB TIUXETAN, Fludarabine, QS-21, Tanespimycin, Chlorhexidine Phosphanilate